DermaLabs (DermaDAO)

Overview

DermaLabs (governed as DermaDAO) is a decentralized-science BioDAO on the Bio Protocol launchpad that reorganizes skincare research around real-world data instead of small, one-off clinical panels. It pairs dermatologist-led formulation with a community that opts into standardized, pre-registered trials, capturing measurable skin changes through an AI-imaging app and rewarding validated data contributions with tokens (bio.xyz). It sits in the same DeSci lineage as VitaDAO and HairDAO, but occupies a distinct niche: the consumer product is the experiment.

The thesis: every bathroom mirror is a laboratory

Skincare is a $190 billion-plus global industry that still validates products on small, short, industry-funded panels – methodologically closer to marketing than to science. DermaLabs' bet is that the largest untapped dataset in dermatology is the one billions of people already generate every morning and night. By standardizing how ordinary users apply a product and photograph the result, it converts routine consumer behavior into a continuously growing longitudinal study across real climates, routines, skin tones, and adherence levels (dermadao.xyz). The product is the data-generation flywheel: buying and using the serum is how a member enters the trial.

Products and SkinScan

DermaLabs intends evidence-first consumer skincare as the on-ramp to its research loop, and the line is not on general sale yet. Its first products are Moon Drops, an evening antioxidant serum combining L-ascorbic acid, alpha-tocopherol, and ferulic acid, and its daytime companion, a UV filter built on Korean sunscreen chemistry. Each purchase credits the buyer BioXP toward the wider Bio ecosystem.

The companion product goes by two names, and the split is worth flagging because it decides which one a reader should search for. Bio Protocol's February 2026 write-up calls it Sol Drops and describes a mineral serum with zinc oxide, titanium dioxide, niacinamide and panthenol. DermaDAO's own surfaces no longer use that name at all: the product page is headed “Moon Drops & Sun Drops” and calls it “The Sun Drops Day UV Filter”, and the roadmap writes the pair as “Moon x Sun Drops” (all read 10 September 2026). The vendor's own name is the one this page treats as current.

The measurement layer is SkinScan, described as an AI-imaging app that turns a phone into a clinically relevant skin lab, quantifying wrinkles, spots, and redness from user photos. On dermadao.xyz, re-read 10 September 2026, it is listed as coming soon behind a waitlist rather than as a shipped tool – and so are the serums themselves and the research arm, Skin Science Labs: all three sit in one strip headed “Projects in development”, each carrying the same “Join the waitlist” control. The design intent is unchanged and worth stating on its own terms: standardized capture would turn a selfie into a comparable data point, so a member's own before/after becomes a row in a shared, auditable dataset rather than an anecdote. Whether that measurement layer exists yet is a separate question from whether the idea is sound, and as of this check it does not.

Decentralized trials and IP

DermaDAO's stated research model is blinded, pre-registered A/B protocols run on-chain: participants follow a defined regimen, keep time-stamped photo journals, and are rewarded for validated contributions, with AI-assisted analysis quantifying changes in measurable skin attributes. Its illustrative study is the LUNAR trial ("Longevity Using Novel Actives for Rejuvenation"), in which Moon Drops serves as the baseline formulation and enhanced variants are tested side by side under standardized protocols, tracked longitudinally rather than at a single endpoint (bio.xyz). Because a design registered up front and data that stays user-owned permit stratified analysis – by diagnosis, skin tone, and age – the model could answer questions a single-panel study cannot.

None of it is running yet. Re-read 10 September 2026, dermadao.xyz still states plainly that "the decentralized trials program is currently in development and will be launching soon", and still invites people to fill in a survey form to become an early contributor and "stand to earn a $SKIN Airdrop". What the page does carry is the design: it commits DermaDAO to "pre-register blinded A/B skincare protocols on-chain", and it names an intellectual-property primitive – but calls it an Intellectual Property Token (IPT), DermaDAO's own term, and never writes "IP-NFT". So the honest present-tense description is a consumer product line still behind a waitlist and a research programme that has been designed and named but not yet opened – a distinction the DAO's own site draws, and one worth preserving here rather than reading the roadmap as the record.

If and when the programme opens, the intended output layer is the IPT, which is the IP-NFT under a house name – the same Molecule-pioneered primitive VitaDAO uses – so a validated finding would become a transparent, community-owned, fundable asset rather than a corporate trade secret. That is the model DermaLabs sits inside by virtue of being a Bio Protocol BioDAO, not a step it has been observed taking.

The science team

DermaLabs is fronted by a working dermatology and cosmetic-chemistry bench rather than a purely crypto-native team (bio.xyz):

• Dr. DTS (Hongseok Kim) – board-certified Korean dermatologist focused on evidence-based K-beauty, and the public face of the launch.
• Jez Marston – physician-scientist with a PhD in immunology and computational biology (Cornell).
• Hyeon Pyo Jhun – cosmetic chemist with 40-plus years in skincare R&D.
• Dongsinne Sohn – health and Web3 operator focused on chronic skin conditions.

The $SKIN token and place in the Bio ecosystem

$SKIN is DermaDAO's utility token: it rewards validated data and product contributions and lets holders govern research direction and funding, with no equity or revenue claim (dermadao.xyz). It launched through Bio Protocol's Ignition Sale mechanism – a Gnosis batch-auction where participants bid stablecoins for a fixed token allocation – in December 2025.

DermaLabs is one of Bio Protocol's incubated BioDAOs, alongside longevity (VitaDAO), hair loss (HairDAO), cryopreservation (CryoDAO), and quantum biology (Quantum Biology DAO). What sets it apart is putting a consumer product line first in the plan and treating it as the recruitment funnel for the science, rather than funding research and tokenizing the output – the clearest example in the BioDAO set of the "real-world DeSci product" model.

Reading the roadmap against the record

DermaDAO publishes a four-phase roadmap, and it should be read as a plan rather than a record, because the page has not moved with the project. Phase 1, dated Q3 2025, is to “Launch CE Ferulic ‘Moon x Sun Drops’”, “Open a DTC storefront” and launch two IPTs. Phase 2, Q4 2025, would “Enroll the first SkinScan-tracked community trial for CE Ferulic (pre-registered)”. Phase 3, Q1–Q3 2026, would “Run dozens of simultaneous, statistically-powered community trials”. Read on 10 September 2026 – the last month of that third window – the storefront is a waitlist, SkinScan is “coming soon”, and the trials programme “is currently in development”.

The phase that dates the page hardest is the last one. Phase 4, 2027+, promises to “Issue $SKIN and seed the DAO treasury” and to “Activate community voting for R&D funding and prioritization” – yet the $SKIN Ignition Sale ran in December 2025, more than a year before the phase that plans it. A roadmap whose closing phase schedules something already done has stopped tracking its own project, which is a useful reminder for any reader of this wiki's Bio Protocol pages: a published roadmap dates the moment it was written, not the state of the thing it describes.

How Caper approaches this

DermaLabs and Caper answer different questions, but they meet on one: who should steer a community-funded effort, and how is that steering earned? DermaDAO rewards contribution with a freely tradeable $SKIN token – data and purchases mint governance power that can then be bought or sold on the open market. Caper takes the opposite stance on the decisive slice of control: taking part in a caper mints a soulbound, non-transferable proof-of-vote token, and since the 11 September 2026 redeploy it mints on exactly one act – one per ranked ballot cast (VOTE_MINT = 1), with buying and selling minting none (fractional, and locked to its holder – its deposit authority is the component itself, with updates permanently denied, per contracts/core/src/caper_dao.rs).

A member's on-chain influence grows with their earned votes, not with their token holdings alone, so a big bag cannot mint its own participation at any price, and can never purchase the record another member already holds. The same earned weight sets what a member redeems on exit. For a research DAO, the honest read is that each model optimizes for something real: $SKIN maximizes liquid, tradeable incentives to contribute data at scale, while Caper's earned, un-sellable weight is built for the case where you specifically do not want steering to be for sale.